Literature DB >> 16484981

Expanding the COL7A1 mutation database: novel and recurrent mutations and unusual genotype-phenotype constellations in 41 patients with dystrophic epidermolysis bullosa.

Johannes S Kern1, Jürgen Kohlhase, Leena Bruckner-Tuderman, Cristina Has.   

Abstract

Dystrophic epidermolysis bullosa (DEB), a heterogeneous hereditary skin disorder characterized by trauma-induced blistering and scarring, affects thousands of families worldwide. The clinical manifestations extend from minor nail dystrophy to severe life-threatening blistering, making early molecular diagnosis and prognostication of utmost importance for the affected families. DEB is caused by mutations in the COL7A1 gene encoding collagen VII in the skin. Molecular diagnostics and genotype-phenotype correlations in DEB remain complex owing to the gene structure, large variety of mutations, high rate of novel mutations, complex protein structure and assembly, and the heterogeneity of phenotypes. Here, we report an efficient strategy for COL7A1 mutation detection using direct automated DNA sequencing and implementation of software tools. With this approach, COL7A1 mutations of 41 DEB families were disclosed. Twenty-four mutations were novel and two recurrent. Elucidation of biological consequences of the mutations helped define disease mechanisms, but also revealed several unusual genotypic and/or phenotypic constellations, which impeded the diagnostics and prognostication. In addition, the studies disclosed a de novo mutation in recessive DEB and two new polymorphisms in the COL7A1 gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16484981     DOI: 10.1038/sj.jid.5700219

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  23 in total

1.  Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes.

Authors:  Roslyn Varki; Sara Sadowski; Jouni Uitto; Ellen Pfendner
Journal:  J Med Genet       Date:  2006-09-13       Impact factor: 6.318

2.  Can type VII collagen injections cure dystrophic epidermolysis bullosa?

Authors:  Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-01       Impact factor: 11.454

3.  Altered gene expression in murine placentas in an infection-induced intrauterine growth restriction model: a microarray analysis.

Authors:  Y A Bobetsis; S P Barros; D M Lin; R M Arce; S Offenbacher
Journal:  J Reprod Immunol       Date:  2010-05-16       Impact factor: 4.054

Review 4.  [Epidermolysis bullosa. An update].

Authors:  H Schumann
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

5.  Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII.

Authors:  Anja Fritsch; Sashko Spassov; Susanne Elfert; Andreas Schlosser; Yannick Gache; Guerrino Meneguzzi; Leena Bruckner-Tuderman
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

6.  Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.

Authors:  Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

7.  Acquired syndactyly in epidermolysis bullosa dystrophica.

Authors:  Inusha Panigrahi; Ketan Kulkarni; Devi Dayal
Journal:  BMJ Case Rep       Date:  2009-06-21

8.  Combinatorial Omics Analysis Reveals Perturbed Lysosomal Homeostasis in Collagen VII-deficient Keratinocytes.

Authors:  Kerstin Thriene; Björn Andreas Grüning; Olivier Bornert; Anika Erxleben; Juna Leppert; Ioannis Athanasiou; Ekkehard Weber; Dimitra Kiritsi; Alexander Nyström; Thomas Reinheckel; Rolf Backofen; Cristina Has; Leena Bruckner-Tuderman; Jörn Dengjel
Journal:  Mol Cell Proteomics       Date:  2018-01-11       Impact factor: 5.911

9.  A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.

Authors:  Anja Fritsch; Stefan Loeckermann; Johannes S Kern; Attila Braun; Michael R Bösl; Thorsten A Bley; Hauke Schumann; Dominik von Elverfeldt; Dominik Paul; Miriam Erlacher; Dirk Berens von Rautenfeld; Ingrid Hausser; Reinhard Fässler; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

10.  A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa families.

Authors:  Natividad Cuadrado-Corrales; Carolina Sánchez-Jimeno; Marta García; María-José Escámez; Nuria Illera; Angela Hernández-Martín; María-José Trujillo-Tiebas; Carmen Ayuso; Marcela Del Rio
Journal:  BMC Med Genet       Date:  2010-09-29       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.